44 results about "Human prostate" patented technology

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

The invention belongs to the technical field of biological medicine, and particularly relates to a prostate cancer organoid culture medium, a preparation method thereof, a prostate cancer organoid and a culture method thereof. The prostate cancer organ culture medium provided by the invention comprises a basic culture medium and a culture additive, and the culture additive comprises FGF-10 (Fibroblast Growth Factor), Zeaxanthin dipalmitate and Polydatin. In the prostate cancer organoid culture medium provided by the invention, the success rate of organoid culture is greatly improved by utilizing the synergistic effect of the FGF-10, the Zeaxanthin dipalmitate and the Polydatin, the cultured prostate cancer organoid is high in growth speed, the passage frequency is remarkably improved, in-vitro culture can be specifically carried out on prostate cancer tissues of people, and the prostate cancer organoid culture medium has the advantages that the prostate cancer tissue culture efficiency is improved; the survival rate and the formation efficiency of the prostatic cancer organs are further improved.

The invention discloses a preparation method of a gold-silicon SERS (Surface Enhanced Raman Scattering) substrate based on femtosecond laser processing and application of a micro-fluidic chip adopting the gold-silicon SERS substrate prepared based on femtosecond laser processing in capture and detection of cancer cells. The base preparation method comprises the following basic steps: S1, processing a micro-pit array on the surface of a silicon wafer through femtosecond laser processing; s2, electrochemically depositing a gold nano spine-shaped structure at the micro-pit array after femtosecond laser processing to prepare an SERS substrate; s3, testing the SERS performance of the substrate; and S4, incubating the substrate aptamer and capturing cancer cells. According to the gold-silicon SERS substrate based on femtosecond laser processing, SERS signals of an object to be detected can be remarkably improved, a large specific surface area is provided, and more detection sites are provided for molecules to be detected. Besides, the micro-pit array and the surface nano spine structure of the SERS substrate can effectively capture the cancer cells, a new method is provided for capturing and detecting the cancer cells, and the SERS substrate has great significance in early screening and diagnosis of human prostate cancer and analysis and research of heterogeneity of the cancer cells.

The invention discloses a 1, 8-disubstituted tryptanthrin derivative and application of the 1, 8-disubstituted tryptanthrin derivative to prevention and treatment of phytopathogen and anti-tumor activity, the general formula of the derivative is shown in (I), and the test result of the compound shown in the general formula on the bacterial activity of phytopathogen shows that the compound has a good antibacterial effect on Xanthomonas oryzae pv. Oryzae, Xanthomonas citri pv. Citri and the like, and can be used for preventing and treating the phytopathogen. The method can be used for developing novel agricultural bactericides. Meanwhile, results of the compound shown in the general formula on tumor cells show that the compound has good in-vitro anti-tumor activity on human chronic myelogenous leukemia cells K562, human lung cancer cell lines A549, human liver cancer cells HepG2, human prostate cancer cells PC3 and the like, and can be used for researching novel anti-tumor drugs. # imgabs0 #

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-human prostate specific membrane antigen (PSMA) antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the antibody are respectively shown as SEQ ID NO.8-10. The antibody with the complementarity determining region sequence provided by the invention can specifically recognize PSMA expressed by cells and tissues, has good affinity in combination with the PSMA, has high recognition sensitivity, can effectively resist the interference of complex non-target protein components in the cells / tissues, has no specific combination with non-target antigens, is suitable for immunological detection of the PSMA, and has good application prospects. The kit is especially suitable for western blot detection and immunohistochemical methods, and can reduce the occurrence rate of false positive and false negative results and improve the accuracy of immunodiagnosis.

A kind of ethenyl indole and medium ring compound and its synthesis method, compound includes axial chiral ethenyl indole and nine-membered ring compound and ethenyl indole and eight-membered ring compound, structural formula is as shown in formula 3 and formula 6 respectively;Synthesis method: with formula 1 compound 3-ethynyl-2-indole methanol and formula 2 compound 2-indole ethanol / formula 5 compound 2-indole methanol as reaction raw material is added to organic solvent, additive is added, under the catalysis of catalyst and under certain temperature condition stirring reaction, TLC is tracked to complete reaction, filter, concentrate, purify and obtain.The ethenyl indole and medium ring compound synthesized in the application, through biological activity test, shows that the two types of derivatives have high sensitivity and strong cytotoxic activity to human prostate cancer cell PC-3.The reaction condition of the application is relatively conventional, the reaction process is mild, simple, low in cost, suitable for industrial large-scale production, and the application range of the method is widened.

The invention belongs to the field of biological medicine, and particularly relates to a small molecule drug conjugate model, in particular to a small molecule drug conjugate based on anisamide targeting human prostate cancer cells as well as a preparation method and application thereof. The micromolecular drug conjugate is used as a prodrug, and is composed of four parts, namely a PEG-modified anisidine target head, a drug connexon composed of a glucuronic acid trigger and a self-closed loop, maleimide and an SN38 cytotoxic drug. According to the prodrug, the targeting capacity of the drug to prostate cancer cells is improved through a PEG-modified anisidine target head, a good drug release system is constructed by a drug linker composed of a glucuronic acid trigger and a self-closed loop, the water solubility and stability of the drug are improved by taking albumin as a carrier, and long-acting circulation in vivo is realized. The compound also shows a remarkable curative effect in the aspect of treating prostatic cancer.

Microfluidic devices, organ-on-a-chip platforms (e.g. mimicking the human prostate gland), and uses thereof are described herein. The microfluidic device includes at least two layers and a porous membrane therebetween. Each layer includes a channel, and the first channel and the second channel are aligned such that a first region of a first channel overlaps with a region of the second channel, and a second region of the first channel does not overlap a second region of the second channel. A disease model using the microfluidic devices includes (i) placing a first type of cells in the first channel and (ii) flowing a first cell culture medium through the first channel. Optionally, in step (i) a second type of cells in the second channel and in step (ii) a second cell culture medium flows through the second channel. The microfluidic devices can be used in drug screening and testing.

Inventors have firstly demonstrated that the transcriptomic signature of PTENpc- / - LSCmed cells is enriched in human MSPC signature, associated to metastases and ADT resistance. Using scRNAseq specifically with sorted PTENpc- / - LSCmed cells, they identified three distinct LSCmed clusters and showed that castration favors the emergence of the most stem-like LSCmed subpopulation by cell plasticity. In the latter, they identified the transcription factor FOSL1 / AP-1 and the kinase PIM1 as relevant therapeutic targets, and they showed that combined inhibition using JQ1, a BET / AP-1 inhibitor, and CX-6258, a pan-PIM kinase inhibitor, efficiently prevents PTENpc / - LSCmed cell growth in organoids. These findings were confirmed in the human prostate HPV10 cell line here identified as a robust model of Club / Hillock cells. Combined drug delivery to castrated PTEN-null mice induced a significant prostate weight decrease associated with the reduction of histopathological phenotypes and dramatically altered organoid-formation capacity of LSCmed cells sorted from these tumors. Accordingly, the drug combination significantly delayed tumor growth of MSPC-like human PC-3 cells subcutaneously injected into castrated immunodeficient mice. Altogether, this work shows a new therapeutic potential of combined FOSL1 and PIM1 targeting to prevent, or at least delay, the growth of MSPC-like cells. Accordingly, the invention relates to i) an inhibitor of FOSL1 and ii) an inhibitor of PIM1, as a combined preparation for use in the treatment of prostate cancer in a subject in need thereof.

The invention belongs to the technical field of prostate cancer diagnosis, and particularly relates to serum 7-dehydrocholesterol as a prostate cancer metastasis and endocrine treatment drug resistance diagnosis marker and application thereof. 7-dehydrocholesterol provided by the invention has different levels in human prostate cancer cell lines such as LNCaP, Du145, PC3 and the like, and is abnormally increased in PC3, so that the 7-dehydrocholesterol can be used as a drug resistance diagnosis marker for prostate cancer metastasis and endocrine therapy; the reagent composition capable of specifically recognizing 7-dehydrocholesterol and generating detectable signals can be used for preparing a prostate cancer detection kit; the 7-dehydrocholesterol provided by the invention has non-invasive, non-invasive and efficient effects as a diagnostic marker, and solves the technical problem of lack of a prostate cancer diagnostic marker in the prior art.

The invention belongs to the technical field of organic synthesis and medicinal chemistry, and discloses efficient synthesis of a novel polycyclic aromatic hydrocarbon derivative 5, 9-di-tert-butyl-12-mesitylene naphtho indolizine phenothiazine and an anti-cancer application of the novel polycyclic aromatic hydrocarbon derivative 5, 9-di-tert-butyl-12-mesitylene naphtho indolizine phenothiazine. According to the compound, a mesitylene group is introduced for the first time on the basis of a naphthoindolizine phenothiazine skeleton. The synthesis conditions are mild, and the yield is as high as 91%. In-vitro anti-cancer activity research shows that the compound has remarkable broad-spectrum anti-cancer activity and shows strong proliferation inhibition on human cervical cancer Hela cells (IC50 = 1.6 mu M), human lung cancer A549 cells (IC50 = 13.29 mu M) and human prostatic cancer PC-3 cells (IC50 = 19.1 mu M). Particularly, the activity on Hela cells is obviously superior to that of a clinical first-line drug cis-platinum. Preliminary toxicity evaluation shows that the toxicity of the compound to human normal umbilical vein endothelial cells (HUVEC) is far lower than that of cancer cells, and the selectivity is good.

The invention relates to BRD4 and p300 / CBP double-target PROTAC molecules as well as a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. The compound has a general formula shown in the specification, wherein L is preferably selected from one of the group; and E is preferably selected from one of the group. The compound disclosed by the invention has remarkable anti-tumor activity on human prostatic cancer cell strains PC-3, DU145 and 22Rv1 in vitro, the IC50 values are all lower than 20nM, and particularly, the IC50 values are all lower than 10nM in the cells PC-3 and DU145. The compound I-c shows the optimal activity, the IC50 values of the compound I-c in PC-3 and DU145 cells are 2.80 nM and 6.62 nM respectively, and the IC50 values of the compound I-c are obviously superior to those of positive control drugs NEO2734, paclitaxel and ARV-771. As a novel BRD4 and p300 / CBP double-target PROTAC molecule, the compound disclosed by the invention has a definite action mechanism and excellent anti-tumor activity, and can be used as a candidate or lead compound for research and development of anti-tumor drugs; the synthesis method is simple and convenient, and has good popularization and application prospects.

The invention discloses a 2-fluoro-3-aliphatic amine tryptanthrin derivative and application of the compound to prevention and treatment of phytopathogen and anti-tumor activity, the general formula of the derivative is as shown in (I), and the test result of the compound as shown in the general formula to the bacterial activity of phytopathogen shows that the compound can be used for preparing the 2-fluoro-3-aliphatic amine tryptanthrin derivative. The compound has a good antibacterial effect on Xanthomonas oryzae pv. Oryzae, Xanthomonas citri pv. Citri and the like, and can be used for developing novel agricultural bactericides. Meanwhile, results of the compound shown in the general formula on tumor cells show that the compound has good in-vitro anti-tumor activity on human chronic myelogenous leukemia cells K562, human lung cancer cell lines A549, human liver cancer cells HepG2, human prostate cancer cells PC3 and the like, and can be used for researching novel anti-tumor drugs. # imgabs0 #

The present invention relates to a method for treating prostate cancer with a combination of an antiandrogen compound and a T-cell engaging molecule that specifically binds to human prostate specific membrane antigen (PSMA) and human CD3. In particular, the present invention relates to a method for treating prostate cancer, including metastatic castration-resistant prostate cancer, in a patient in need thereof, comprising administering to the patient one or more cycles of an antiandrogen compound in combination with a PSMA-targeted T-cell engaging molecule, wherein administration of a first dose of the antiandrogen compound is delayed relative to administration of a first therapeutic dose of the PSMA-targeted T-cell engaging molecule during the first cycle.

A vapor delivery needle and method is provided that is adapted for treating prostate cancer. The energy delivery probe can apply condensable vapor energy to tissue, such as a peripheral zone tissue in a human prostate. In one method, a needle is introduced into peripheral zone tissue of a human prostate, and vapor media is delivered through the needle to ablate peripheral zone tissue without ablating non-peripheral zone tissue. Systems for treating prostate cancer with vapor therapy are also provided.

The invention discloses a polypentylene-based adamantane-type benzophenone compound and a preparation method and application thereof, and belongs to the field of medical technology. The polypentylene-based adamantane-type benzophenone compound of the invention is extracted with golden silk plum stems by acetone, concentrated to obtain a crude extract, suspended in water, extracted with petroleum ether and dichloromethane in sequence, the dichloromethane extract is loaded onto a silica gel chromatographic column, and after two silica gel chromatographic column purifications, the obtained eluent is recrystallized from petroleum ether to obtain. Experimental studies have shown that the compound has a very strong growth inhibitory effect on human acute promyelocytic leukemia cells HL-60, human prostate cancer cells PC-3, and human colon adenocarcinoma cells Caco-2, and has the prospect of preparing clinical tumor prevention and treatment drugs.

The present invention provides an anti-tumor compound, an anti-tumor drug, a preparation method and an application thereof, belonging to the technical field of pharmaceutical preparation. The general structural formula of the compound provided by the present invention is #imgabs0#. In vitro anti-tumor activity tests of this type of compound found that it has an obvious inhibitory effect on the growth of human prostate cancer cell PC3. Among them, compound D17 has significant anti-tumor activity against five human prostate cancer cells (PC3, DU145, C42B, LNCAP, 22RV1) and shows concentration dependence, and can be used as a lead compound or a candidate compound for the development of anti-tumor drugs.

The invention relates to an aporphine-benzylisoquinoline alkaloid dimer as well as a preparation method and application thereof, and belongs to the field of natural medicines and biological medicines. The aporphine-benzylisoquinoline alkaloid dimer has a structural general formula shown in the specification, in the formula, R1, R2, R3, R4, R5, R6, R7 and R8 are independently selected from hydrogen, methoxyl, hydroxyl or two adjacent substituent groups are methylenedioxy, so that a five-membered ring is formed; and R9 is selected from hydrogen, methoxyl or hydroxyl. Six novel aporphine-benzylisoquinoline alkaloid dimers are extracted and separated from roots of thalictrum omeiensis, and through detection, the aporphine-benzylisoquinoline alkaloid dimers have obvious growth inhibition effects on human acute promyelocytic leukemia cells HL-60 and human prostate cancer cells PC-3, and have the prospect of preparing medicines for preventing and treating tumors.

The invention relates to a vinyl indole ring compound and a synthesis method thereof, the compound comprises an axial chiral vinyl indole nine-membered ring compound and a vinyl indole eight-membered ring compound, and the structural formulas are respectively shown as a formula 3 and a formula 6; the synthesis method comprises the following steps: adding a compound 3-ethynyl-2-indolyl carbinol in a formula 1 and a compound 2-indolyl carbinol in a formula 2 / 2-indolyl carbinol in a formula 5 as reaction raw materials into an organic solvent, adding an additive, carrying out a stirring reaction under the catalysis of a catalyst and a certain temperature condition, tracking the reaction by TLC until the reaction is complete, filtering, concentrating, and purifying to obtain the compound 3-ethynyl-2-indolyl carbinol. According to the vinyl indole ring compound synthesized by the invention, biological activity tests show that the two derivatives have relatively high sensitivity and very strong cytotoxic activity to human prostate cancer cells PC-3. The method is relatively conventional in reaction condition, mild and simple in reaction process, low in cost and suitable for industrial large-scale production, and the application range of the method is widened.

A vapor delivery needle and method is provided that is adapted for treating prostate cancer. The energy delivery probe can apply condensable vapor energy to tissue, such as a peripheral zone tissue in a human prostate. In one method, a needle is introduced into peripheral zone tissue of a human prostate, and vapor media is delivered through the needle to ablate peripheral zone tissue without ablating non-peripheral zone tissue. Systems for treating prostate cancer with vapor therapy are also provided.

This invention provides a substituted tetrahydroquinoline derivative and its application, which is a class of compounds with AR antagonistic activity. These compounds competitively bind to androgens, blocking AR activation and inhibiting the AR signaling pathway. Experiments have confirmed that the synthesized compounds all possess excellent AR antagonistic activity, showing strong inhibitory activity in the human prostate cancer cell line LNCaP. Therefore, they can be used to prepare drugs for treating diseases with abnormal androgen receptor expression, such as tumors including but not limited to prostate cancer, metastatic prostate cancer, castration-resistant prostate cancer, breast cancer, and ovarian cancer. The general structural formula of the compounds is shown in formula (a):

The present invention discloses a tertiary amide compound containing a naphthyl group, a preparation method, and an application thereof, belonging to the field of pharmaceutical technology. In vitro antitumor activity tests show that the tertiary amide compound containing a naphthyl group has a significant inhibitory effect on the growth of various tumor cells (human esophageal cancer cell line EC9706, human gastric cancer cell line SGC7901, human colorectal adenocarcinoma cell line HT-29, human gastric cancer cell line MGC-803, human breast cancer cell line MCF7, and human prostate cancer cell line PC-3). Its activity is significantly superior to that of the antitumor drug 5-fluorouracil, and it can be used as a lead compound or candidate compound for the development of broad-spectrum antitumor drugs.

The invention relates to a preparation method and application of aporphine-protoberberine alkaloid dimers, and belongs to the field of natural medicines and biological medicines. The aporphine-protoberberine alkaloid dimer disclosed by the invention has a structural general formula shown in the specification, in the formula, R1, R2, R3, R5, R6, R7, R8 and R9 are independently selected from hydrogen, methoxyl, hydroxyl or two adjacent substituent groups are methylenedioxy, so that a five-membered ring is formed; r4 is selected from hydrogen, methoxyl or hydroxyl. Six novel aporphine-protoberberine alkaloid dimers are extracted and separated from thalictrum omeiensis roots, and tests show that the aporphine-protoberberine alkaloid dimers have obvious growth inhibition effects on human acute promyelocytic leukemia cells HL-60 and human prostate cancer cells PC-3, can cause HL-60 cell cycle arrest in an S phase, induce HL-60 cell apoptosis, and can be used for preparing the aporphine-protoberberine alkaloid dimers. The compound has a prospect of preparing medicines for preventing and treating tumors.

A surgical training model for simulating human prostate surgery may include a harvested porcine urethra. A harvested porcine vagina surrounds a portion of the harvested porcine urethra to define a simulated human prostate.

Aspects of the present disclosure relate to methods and compositions related to the preparation of immune cells, including engineered T cells having T cell receptors targeting human prostate acid phosphatase (PAP) and useful in prostate cancer therapy.

Aspects of the present disclosure relate to methods and compositions for preparing immune cells, including engineered T cells, with T cell receptors that target human prostatic acid phosphatase (PAP) and are useful in treating prostate cancer. In certain embodiments of the present invention, the T cell receptors that recognize / bind to PAP target at least one polypeptide epitope selected from ILLWQPIPV (SEQ ID NO: 47), TLMSAMTNL (SEQ ID NO: 48), IRSTDVDRTL (SEQ ID NO: 52), IMYSAHDTTV (SEQ ID NO: 55), KVYDPLYCESV (SEQ ID NO: 58), LLLARAASLSL (SEQ ID NO: 59), and LLFFWLDRSVLA (SEQ ID NO: 62).

The utility model relates to the technical field of medical equipment, and discloses a teaching model for simulating prostate laser vaporization or enucleation, which comprises a shell model in a human prostate shape and used for simulating a human prostate surgery envelope structure and a blood vessel structure of an envelope walking towards an inner gland, the prostate surgery envelope structure and the blood vessel structure are integrally formed; the upper portion of the shell model is provided with a first pipe opening used for being connected with a bladder model, the two sides of the upper portion of the shell model are each provided with a second pipe opening, internal ports of the second pipe openings are communicated with a vascular structure, and external ports of the second pipe openings are used for being connected with an external infusion apparatus to simulate blood circulation. The lower portion of the shell model is provided with a third pipe opening used for being connected with the urethra model. The internal model comprises a prostate urethra part and a prostate internal gland structure. The model is closer to a real hyperplasia gland in texture and physical characteristics, so that a doctor can obtain touch and force feedback which is very similar to that of actual operation when performing resectoscope combined laser vaporization or enucleation training.

The invention discloses a composition for treating prostatic cancer and application thereof. The composition is prepared from naringenin and cis-platinum. The application is the application of the composition for treating the prostatic cancer in preparation of drugs for treating the prostatic cancer. When the naringenin is combined with the cis-platinum, the inhibition effect on human prostate cancer cells DU-145 is obviously enhanced, a synergistic effect is achieved, and the naringenin and the cis-platinum have very small toxicity on normal HL-7702 cells. The naringenin combined with clinical drugs shows excellent in-vivo and in-vitro anti-tumor activity on human prostate cancer cells, has potential medicinal value and is expected to be used for preparing various anti-tumor drugs.

The present invention relates to a beauvericin composition for inhibiting the proliferation of human prostate cancer cells and a preparation method thereof, wherein the composition comprises beauvericin and an indole compound, wherein the mass ratio of the beauvericin to the indole compound is 1:(0.2-0.5). The beauvericin and the indole compound in the composition have a significant inhibitory effect on the proliferation of human prostate cancer cells.

The present invention provides the use of Cistancheside F or a pharmaceutically acceptable salt thereof in the preparation of an anti-tumor drug. In vitro experiments show that Cistancheside F has significant inhibitory activity against a variety of tumor strains, including human lung cancer cells A549, human gastric adenocarcinoma cells AGS-CAS9, human liver cancer cells SK-HEP-1, human bladder cancer cells RT112, human cervical cancer cells Hela, human prostate cancer cells PC-3, and human neuroblastoma cells SH-SY5Y. Animal experiments show that Cistancheside F has a good in vivo anti-tumor effect and has a significant therapeutic effect on a variety of tumors, such as bladder cancer and liver cancer. Cistancheside F has strong anti-tumor activity and has broad application prospects.